Antidepressants in Inflammatory Bowel Disease: A Systematic Review

  title={Antidepressants in Inflammatory Bowel Disease: A Systematic Review},
  author={Benjamin Macer and Stephanie L. Prady and Antonina Mikocka-Walus},
  journal={Inflammatory Bowel Diseases},
Background: Antidepressants are commonly used to treat symptoms of anxiety and depression in inflammatory bowel disease (IBD. [] Key Method Results: Fifteen eligible studies included in the review (1 randomized controlled trial, 2 cohorts, 1 case–control, 1 cross-sectional survey, 1 qualitative, 2 audits, 1 case series, and 6 case reports) examined a range of antidepressants. Twelve studies suggested that antidepressants have a positive impact on IBD course. Nine studies reported anxiety and depression as…

Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.

The efficacy and safety of antidepressants for treating anxiety and depression in IBD, and the effects of antidepressants on quality of life (QoL) and managing disease activity in I BD are assessed.

Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial

Venlafaxine has a significantly beneficial effect on QoL, IBD activity, and mental health in patients with IBD with comorbid anxious or depressive symptoms.

The Effect of Antidepressants on the Course of Inflammatory Bowel Disease

Antidepressants may have some beneficial effects on the natural history of IBD, but larger studies with longer follow-up are required to determine whether these effects are limited to patients with abnormal mood.

Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression

Patients with a history of depression were more likely to be diagnosed with IBD and antidepressant treatments were selectively protective for Crohn’s disease and UC, which may impact counselling and management of depression and IBD.

Bidirectional brain–gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis

Bidirectional effects of the brain–gut axis are present in IBD and may influence both the natural history of the disease and psychological health.

Depression in Women With Inflammatory Bowel Disease: A Multifaceted Approach for a Multidimensional Problem.

Evidence on sex-based differences in depression pathogenesis and the effect of depression on various factors associated with IBD that affect women's lives, including sexual dysfunction, body image dissatisfaction, fertility, and overall quality of life is presented.

The emerging role of mood disorders in inflammatory bowel diseases.

Monitoring for mood disorders should become a part of the multi-disciplinary and holistic approach to patients with IBD, based on current literature searched in PubMed.

The Influence of Antidepressants on the Disease Course Among Patients With Crohn’s Disease and Ulcerative Colitis—A Danish Nationwide Register–Based Cohort Study

In this nationwide study, antidepressant use was found to be beneficial on the disease course among patients with UC and CD, particularly in patients with no use of antidepressants before IBD onset.

The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time.

Symptoms of depression and anxiety are associated with disease activity in IBD over time and reducing these symptoms should be incorporated into the management of IBD.



Adjuvant therapy with antidepressants for the management of inflammatory bowel disease.

The efficacy and safety of antidepressants for treating anxiety and depression in IBD, and the effects of antidepressants on quality of life (QoL) and managing disease activity in I BD are assessed.

Can antidepressants influence the course of inflammatory bowel disease? The current state of research

Overall, the studies suggest a positive impact of antidepressants on inflammation in IBD, however, good-quality human data are lacking and more RCTs are needed.

Antidepressants and inflammatory bowel disease: a systematic review

Although most of reviewed papers suggest a beneficial effect of treatment with antidepressants in patients with IBD, due to the lack of reliable data, it is impossible to judge the efficacy of antidepressants in IBD.

Controversies Revisited: A Systematic Review of the Comorbidity of Depression and Anxiety with Inflammatory Bowel Diseases

The high rates of anxiety and depression for those with IBD, particularly when disease is active, warrant a systemic approach to screening and treatment.

Do Antidepressants Influence the Disease Course in Inflammatory Bowel Disease? A Retrospective Case‐Matched Observational Study

Antidepressants, when used to treat concomitant mood disorders in IBD, seem to reduce relapse rates, use of steroids, and endoscopies in the year after their introduction, suggesting the need for a prospective controlled trial to evaluate their effects on disease course in patients with IBD.

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis

Antidepressants are effective in the treatment of IBS and there is less high-quality evidence for routine use of psychological therapies in IBS, but available data suggest these may be of comparable efficacy.

Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis

Antidepressants and some psychological therapies are effective treatments for IBS, and summary estimates of treatment effect have remained remarkably stable since the previous meta-analysis.

A magic pill? A qualitative analysis of patients’ views on the role of antidepressant therapy in inflammatory bowel disease (IBD)

Antidepressants seem to be well tolerated by IBD patients and the positive attitude towards antidepressants in these participants may make the conduct of clinical trials to further assess for any specific role on IBD course feasible.

Tricyclic Antidepressants for Management of Residual Symptoms in Inflammatory Bowel Disease

In a clinical practice setting, TCA use led to moderate improvement of residual gastrointestinal symptoms in IBD patients for whom escalation of IBD therapy was not planned.